Darzalex Faspro Receives New Indication Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: stocktwits
- New Indication Approval: Darzalex Faspro has received FDA approval for newly diagnosed multiple myeloma patients, marking its twelfth indication and fifth for this patient group, indicating ongoing expansion in treatment options.
- Clinical Trial Results: The approval is based on a trial involving 395 patients, demonstrating that the combination therapy achieved a higher percentage of minimal residual disease (MRD) negativity at 22 months compared to VRd alone, highlighting significant treatment efficacy.
- Sales Growth: Johnson & Johnson's oncology segment reported sales of $25.38 billion, a 22.1% year-on-year increase, with Darzalex revenue soaring by 95.9% to $1.89 billion, further solidifying its market position.
- Positive Market Reaction: Retail sentiment on Stocktwits for JNJ stock remained in the 'bullish' territory over the past 24 hours, with high message volume, reflecting investor confidence in the company's growth potential.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 221.490
Low
190.00
Averages
218.50
High
240.00
Current: 221.490
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
